New Melanoma Drugs Raising Survival Rates

Ten years ago, getting a diagnosis of advanced melanoma was akin to a death sentence, with most patients dying six to nine months later. Now a trial of two immunotherapy drugs, nivolumab and ipilimumab, showed that 52 percent of patients taking both were still alive after five years, with some in complete remission.